Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 17/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6798038 | 0.79 | OPRM1 (0.40) | OPRM1KDM4EGRIN1GRIN2AGRIN2B | |
| SCHEMBL6799193 | 0.79 | MEN1 (0.46) | — | |
| SCHEMBL6249722 | 0.77 | OPRM1 (0.56) | OPRM1KDM4EGRIN1GRIN2AGRIN2B | |
| SCHEMBL6275107 | 0.76 | ALDH1A1 (0.44) | OPRM1KDM4EGRIN1GRIN2AGRIN2B | |
| SCHEMBL6802473 | 0.75 | OPRM1 (0.47) | OPRM1KDM4EGRIN1GRIN2AGRIN2B | |
| SCHEMBL20777845 | 0.75 | KDM4E (0.47) | OPRM1KDM4EGRIN1GRIN2AGRIN2B | |
| SCHEMBL15863115 | 0.75 | GRIN1 (0.47) | OPRM1KDM4EGRIN1GRIN2AGRIN2B | |
| SCHEMBL32670418 | 0.72 | GRIN1 (0.41) | OPRM1KDM4EGRIN1GRIN2AGRIN2B | |
| SCHEMBL24608764 | 0.72 | GRIN1 (0.44) | OPRM1KDM4EGRIN1GRIN2AGRIN2B | |
| SCHEMBL6180757 | 0.71 | SLC6A9 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063643-A1 | Bombesin antagonists | PFIZER INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063643-A1 | Bombesin antagonists | BRS3, NPSR1, GNRHR | OPRM1 124/4885KDM4E 3172/4885GRIN1 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.